Metformin also suppressed dipeptidyl peptidase-4 (DPP-4) inhibitor-induced EMT via the suppression of mechanistic target of rapamycin (mTOR) signaling in breast cancer [70]. This evidence concerns the gene MTOR and breast carcinoma.